Home
Specialisti
Pubblicazioni
CIRN Divulga
I nostri Specialisti
Home
Specialisti
Giacomo Lus
Contatti
Phone : +39 081 5666 788
Enable JS
Affiliazione : Università degli Studi della Campania Luigi Vanvitelli
Profilo Ricercatore
Giacomo Lus
Neurologo
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire
"Borderline" idiopathic CD4+ T-cell lymphocytopenia presenting with atypical progressive multifocal leukoencephalopathy
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
Therapeutic Plasmapheresis: A Revision of Literature
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Disability assessment using Google Maps
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
Correction to: Disability assessment using Google Maps
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
Identifying Cladribine prescription pattern in MS: an Italian multicentre study
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
Signs and symptoms of COVID-19 in patients with multiple sclerosis
A real-world study of alemtuzumab in a cohort of Italian patients
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
The multidimensional assessment of body representation and interoception in multiple sclerosis
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
Switch from fingolimod to ozanimod for safety or intolerance reasons
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic Study
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
Fingolimod reduces the clinical expression of active demyelinating lesions in MS
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
Multiple Sclerosis Progression and Relapse Activity in Children
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
[Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register]
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study
Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis
Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
Prognostic indicators in pediatric clinically isolated syndrome
Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register
Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study
A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy
Long-term effects of asymmetrical posture in boxing assessed by baropodometry.
Quantitative Evaluation of Upright Posture by x-Ray and 3D Stereophotogrammetry with a New Marker Set Protocol in Late Onset Pompe Disease.
Migraine as possible red flag of PFO presence in suspected demyelinating disease
Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients.
Revelation of a New Mitochondrial DNA Mutation (G12147A) in a MELAS/MERFF Phenotype
Charcot-Marie-Tooth disease with giant axons: a clinicopathological and genetic entity.
Abnormal accumulation of tTGase products in muscle and erythrocytes of chorea-acanthocytosis patients.
Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
"Hidden" symptoms drive progression independent of relapse activity in relapsing-onset multiple sclerosis patients
A long term multicenter observational study on the efficacy and safety of alemtuzumab in multiple sclerosis highly active naive patients
Alemtuzumab-related lymphocytes subset dynamics and disease activity or autoimmune adverse event: real world evidence
Angiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches
Assessing treatment response in pediatric multiple sclerosis patients
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register
Drivers of therapy switch in relapsing multiple sclerosis: a study from the Italian MS Registry
Exploring the reasons behind Ocrelizumab infusions delay during the first wave of COVID-19 pandemic in Italy: results of a survey among MS centers
Extended vs standard interval dose in Ocrelizumab treated MS patients during COVID-19 pandemic: an Italian experience
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Management of ocrelizumab in MS patients during the COVID-19 pandemic: an observational registry-based study
Ocrelizumab extended dosing in Primary Progressive Multiple Sclerosis during the COVID-19 pandemic: a multicenter experience
Predictors of cladribine effectiveness in multiple sclerosis: a real-world, multicenter, two-year follow-up study
Progression independent of relapse activity can occur in paediatric-onset multiple sclerosis and can be prevented by disease modifying drugs
Progression independent of relapse activity is the main determinant of disability accumulation in relapsing-onset multiple sclerosis patients
Relapse associated worsening and progression independent of relapse according to age in multiple sclerosis
Therapeutic choices and disease activity after the end of Cladribine treatment: an Italian multicenter study (CladStop)
Trajectories of disability and relapse-rate in na ve patients on oral drugs: results from the Italian Multiple Sclerosis Register
Alemtuzumab-related lymphocytes subset dynamics and disease activity or autoimmune adverse event
Assessing treatment response in pediatric multiple sclerosis patients
Autologous hematopoietic stem cell transplantation reduces disability progression in patients with secondary progressive multiple sclerosis: results from the Italian MS Register
Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients
Exit-strategies in Natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study
Exit-strategy in Natalizumab responders RRMS patients: an Italian comparison among Ocrelizumab, Rituximab and Cladribine
Italian multicenter observational study on real-life experience with alemtuzumab in naive patients with aggressive multiple sclerosis
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis
Long term disability progression in early and late onset pediatric multiple sclerosis patients
Long-term disability progression in childhood and adolescent onset multiple sclerosis patients
Natural history of multiple sclerosis with childhood and adolescence onset
Observational study on real-life experience with alemtuzumab in naive patients with aggressive Multiple Sclerosis
Ocrelizumab modifies circulating immune asset in relapsing-remitting multiple sclerosis subjects
Ocrelizumab treatment in multiple sclerosis: a real world observational multi-center study to confirm efficacy on disability accrual and explore prognostic factors of response to treatment
Ocrelizumab treatment in multiple sclerosis: Prospective real world observational multi-center study in Campania, Italy
PAS-positive lymphocytes vacuoles possible markers of impaired autophagy in multiple sclerosis
Progression independent of relapse activity in early multiple sclerosis patients
Progression independent of relapse activity in early multiple sclerosis patients and risk of secondary progression: an Italian multicentre study
Progression independent of relapse activity in paediatric, adult and late-onset multiple sclerosis patients
Rebound of multiple sclerosis in patients treated with anti CD20 after discontinuation of rituximab
Relapse-associated worsening and progression independent of relapse activity in an Italian multicentre cohort of early multiple sclerosis patients
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration
The risk of COVID-19 in people with multiple sclerosis: a case-control study from the Italian MS Register
Trajectories of disability accrual according to age in DMT treated multiple sclerosis cohorts from the Italian MS registry
Two year relapse-free and NEDA status with Cladribine in a real life population: a multicentre study
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis
Baseline Patient and Caregiver Characteristics From a Prospective, Noninterventional, Real-World Study (REALITY) on the Effect of Alemtuzumab on Fatigue and Other Patient- and Caregiver-Reported Quality-of-Life Outcomes in Patients With RRMS
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
Body mass Index influence CD20 dynamics in MS patients treated with Ocrelizumab
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study
Comparison of disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies Strategies for disease modification
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis
Disability assessment in the Google Maps era: a feasibility study to explore a new clinical opportunity
Disease modifying treatment may delay time to wheelchair in primary progressive multiple sclerosis: a real-life cohort Pharmacological management of progressive MS
Evaluation of T and B lymphocytopenia in patients treated with ocrelizumab switching from other treatments compared to naive
Injectable versus oral first-line disease-modifying therapies: results from italian ms register
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series
Italian consensus on treatment of spasticity in multiple sclerosis
Italian prospective multicentric observational real-life study of aggressive relapsing remitting multiple sclerosis treated with alemtuzumab
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
Motor disability assessment in the Google Maps era: a feasibility study to test a digital tool
Mri activity and extended interval of natalizumab dosing: a multicenter italian study
Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies
Risks associated with wash-out duration when switching from fingolimod to cell-depleting agents
Towards a validated secondary progressive multiple sclerosis definition: a study from the italian ms register
12-months prospective Pentraxin-3 and metabolomic evaluation in MS patients treated with glatiramer acetate
A real-world study of Alemtuzumab in a cohort of Italian patients
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis
Clinical predictors of dimethil-fumarate response in multiple sclerosis: a real life multicentre study
Correction to: How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study (Journal of Neurology, (2019), 266, 12, (3038-3046), 10.1007/s00415-019-09527-2)
Defining the risk factors for the conversion to secondary progressive multiple sclerosis: a retrospective cohort study of the Italian MS Register
Disability assessment in the Google Maps era: a pilot study
Disability improvement after alemtuzumab is associated with T2 lesion volume shrinkage in multiple sclerosis
Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience
Exposure to disease modifying drugs reduces disability progression in pediatric-, adult- and late-onset relapsing multiple sclerosis: real world data from the Early Multiple Sclerosis Italian Cohort (E-MUSIC)
How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study
Is the antibody titer really useful to verify the immunization of VZV Vaccine in MS patient treated with Fingolimod?
Patients reported outcome measures from relapsing remitting people with multiple sclerosis on first line disease modifying therapies in a real world settin
The Impact of Cognitive Testing on Disability Measurement during the Follow-up of People with Multiple Sclerosis
The Italian multiple sclerosis register
Treatment choice after natalizumab discontinuation: results from an Italian multicenter retrospective study
Extended interval dosing of natalizumab: is efficacy preserved?
INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin
Italian prospective multicenter observational study on real-life experience with alemtuzumab in naive patients with aggressive relapsing remitting multiple sclerosis: initial impressions
Prospective real world observational multi-center study in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Campania, Italy
Two-year assessment of No Evidence of Disease Activity (NEDA-3) and disability regression in patients with aggressive multiple sclerosis treated with alemtuzumab
"Taste", a pilot study: Palatability and oral cavity tolerability of Sativex and possible improvement measures in multiple sclerosis patients with resistant spasticity
Adiponectin as a possible biomarker in multiple sclerosis
Cognitive impairment as prognostic factor in pediatric and juvenile multiple sclerosis
Fingolimod reduces the clinical expression of active demyelinating lesions in MS
Integrated motor and cognitive rehabilitation in multiple sclerosis: A controlled study
Patent foramen ovale: red flag in radiologically isolated syndrome
Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: Results from a real-world, observational EXCHANGE study
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and Orientation Tests
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and Orientation Tests (iEDSS)
A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterisation and genetic correlations
A cluster of progranulin C157KFSX97 mutations in southern Italy: clinical characterization and genetical correlations
Assessment of No Evidence of Disease Activity (NEDA-3) in alemtuzumab-treated patients with aggressive multiple sclerosis who failed multiple disease-modifying drugs
Cost minimization analysis of BoNT-As in the treatment of upper limb spasticity and cervical dystonia
Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
Intracranial extension of orbital inflammatory pseudotumor: A case report and literature review
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
Patent foramen ovale: red flag in radiologically isolated syndrome
PERSONALIZED MEDICINE IN THE CLINICAL PRACTICE: THE ROLE OF FUNCTIONAL GENOMICS RESEARCH CENTRE CETAC" CASERTA (ITALY) THE 04/05 DECEMBER 2015
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
The brief international cognitive assessment for multiple sclerosis (BICAMS) for the evaluation of the EDSS cerebral functional score
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study
Treatment withdrawal in relapsing-remitting multiple sclerosis: A retrospective cohort study
Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome
Multicenter, prospective, observational study aimed at evaluating SAtivex efFEcts (effectiveness and tolerability) in a large population of Italian multiple sclerosis patients: SA. FE. study
Treatment of neuromyelitis optica with rituximab: further insights on efficacy, safety and dosing regimen from 73 Italian patients
MOLECULAR DIAGNOSTICS IN THE CLINICAL PRACTICE" RESEARCH CENTRE CETAC" CASERTA (ITALY) THE 23/24 MAY 2014
NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS PATIENTS: A MULTICENTER EXPERIENCE IN CLINICAL PRACTICE IN ITALY
Safety of the first dose of fingolimod for multiple sclerosis: Results of an open-label clinical trial
Endovascular treatment of CCSVI in patients with multiple sclerosis: Clinical outcome of 462 cases
Fluctuations of MS births and UV-light exposure
Natalizumab in pediatric multiple sclerosis: Results of a cohort of 55 cases
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an italian cohort of 251 cases
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an Italian cohort of 462 cases
Isolated transient blindness and isolated oculomotor nerve palsy secondary to single mesencephalic metastases: Report of 2 cases
Natalizumab in paediatric multiple sclerosis: long-term results of 55 cases
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: A head-to-head retrospective study
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
Long-term efficacy and tolerability of natalizumab treatment in multiple sclerosis patients: a multicentre experience in Italy
Natalizumab is safe and effective in the treatment of active paediatric MS patients
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis
Tumor necrosis factor- and insulin-like growth factor-1 levels in patients with relapsing-remitting multiple sclerosis receiving interferon-1a
The real life impact of early versus delayed treatment of interferon beta on long-term disability progression in relapsing-remitting multiple sclerosis
Azathioprine and interferon β1a in relapsing-remitting multiple sclerosis patients: Increasing efficacy of combined treatment
Autoantibodies in multiple sclerosis patients before and during IFN-β1b treatment: Are they correlated with the occurrence of autoimmune diseases?
Unusual manifestation of vertebral osteoid osteoma: Case report
Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study
Thyroid function and autoimmunity during interferon β-1b treatment: A multicenter prospective study
CTG repeat number in the nonaffected allele of myotonic dystrophy patients is not critical for disease expression
Histopathological heterogeneity and cytopathological similarity of findings in different muscles of two brothers affected by rigid spine syndrome
Normalization of short‐chain acylcoenzyme a dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme a dehydrogenase—deficient myopathy
